CLINICAL & FORMULARY MANAGEMENT STRATEGY
Review Formulary Management Considerations for Opportunities and Strategies and P&T Committee Planning Support
Access Published Guidelines, Health Outcomes, Pharmacoeconomics, and Clinical Trials
Anticipate Market Shifts, Pipeline Events, Manufacturer
Life-Cycle Management Strategies, and
Financial Implications
Understand Key Clinical, Cost, Utilization, Reimbursement, and Market-Competition Factors
IPD's Payer & Provider Insights combine advanced pharmaceutical landscape market visibility with a team of Executive Clinical Pharmacists to provide comprehensive pharmacy and therapeutic management strategy, supporting formulary, clinical, contracting, and market-access decisions.
â
Our subscribers gain around-the-clock access to IPD's proprietary web platform, real-time alerts, comprehensive reports, new drug reviews, podcast episodes, and expert consultations.
-
In-depth analysis regarding drug availability, clinical data, clinical pipeline tracking, evidence-based clinical pathways, preferred products, and site of care
ââ
-
Disease class-specific strategy reports, drug alerts, pipeline trend reports, and new-drug reviews
-
Assessments of potential new brand product prevalence and pricing impacts prior to launch
-
Extensive trend analysis examining brand vs. generic clinical pathways, cost-effective therapies, and payer perspectives
-
Pricing specific to competitive landscape including generic-launch projections, FDA action dates, sales, therapy costs, and price changes
-
Trend reports highlighting disease classes and drug events important to payers, systems, and manufacturers throughout the country
â
-
Clinical criteria, formulary coverage, step therapy, and limited distribution network tracking
Explore Recent Reports
July 2026
Novel Drugs in the Oncology Pipeline for 2H 2026
IPD Analytics has released a new report: "Novel Drugs in the Oncology Pipeline for 2H 2026."
Following a relatively limited first half of the year, the 2H 2026 oncology pipeline is notably more robust, featuring multiple novel agents anticipated across solid tumors and hematologic malignancies. The pipeline includes first-in-class and potentially best-in-class therapies spanning targeted treatments, antibody-drug conjugates (ADCs), radiopharmaceuticals, and cellular therapies.